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Abstract
Background The relationship between obesity and adverse health is well established, but little is known about the con-
tribution of DNA methylation to obesity-related health outcomes. This study tests associations between an epigenetic score
for body mass index (BMI) and health-related, cognitive, psychosocial and lifestyle outcomes in the Lothian Birth Cohort
1936. This study also tests whether these associations are independent of phenotypic BMI.
Method Analyses were conducted using data from the Lothian Birth Cohort 1936 (n= 892). Weights for the epigenetic
BMI score were derived using penalised regression on methylation data from unrelated Generation Scotland participants
(n= 2562). Associations were tested for replication in an independent sample: the Lothian Birth Cohort 1921 (n= 433).
Results A higher epigenetic BMI score was associated with higher BMI (R2= 0.1), greater body weight (R2= 0.06), greater
time taken to walk 6 m, poorer lung function and poorer general physical health (all R2= 0.02), greater levels of triglycerides
(R2= 0.09), greater %total HbA1c (R2= 0.06), lower levels of high-density lipoprotein cholesterol (HDL; R2= 0.08), higher
HDL ratio (HDL/total cholesterol; R2 = 0.03), lower health-related quality of life, physical inactivity, and greater social
deprivation (all R2= 0.02). The epigenetic BMI score (per SD) was also associated with type 2 diabetes (OR 2.17, 95% CI 1.67,
2.84), cardiovascular disease (OR 1.45, 95% CI 1.24, 1.71) and high blood pressure (OR 1.30, 95% CI 1.13, 1.49; all p <
0.00026 after Bonferroni correction). Associations were replicated for BMI (R2= 0.06), body weight (R2= 0.04), health-related
quality of life (R2= 0.02), HbA1c (R2= 0.07) and triglycerides (R2= 0.07; all p < 0.0045 after Bonferroni correction).
Conclusions We observed and replicated associations between an epigenetic score for BMI and variables related to poor
physical health and metabolic syndrome. Regression models with both epigenetic and phenotypic BMI scores as predictors
accounted for a greater proportion of variance in all outcome variables than either predictor alone, demonstrating inde-
pendent and additive effects of epigenetic and phenotypic BMI scores.
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Introduction
Body mass is a complex trait that demonstrates a high
degree of variance in the general population [1]. It is
determined by the contribution of genetic, lifestyle, phy-
siological and psychosocial factors, but together these fac-
tors fail to fully explain the inter-individual variation in the
most widely used clinical measure of body mass, the body
mass index (BMI; kg/m2). Through recent advances in
genomic analysis, we are now able to test whether obesity-
related adverse health and disease may, in part, inﬂuence or
be inﬂuenced by epigenetic changes, with the ultimate aim
of more accurately predicting health outcomes.
Several recent studies have suggested links between BMI
and DNA methylation: epigenome-wide association studies
(EWAS) have identiﬁed CpG sites associated with BMI at
loci involved in lipid and lipoprotein metabolism, blood
lipid levels and inﬂammatory pathways [2–4]. Shah and
colleagues [5] also found that methylation proﬁles asso-
ciated with BMI accounted for 6.9% of the variance in BMI,
independently of genetic proﬁles (polygenic scores), in a
group of 1366 individuals from the Lothian Birth Cohort
(LBC), which is the sample being studied in the present
report.
A growing body of research examining the associations
between DNA methylation and health assumes that expo-
sures to adverse environmental stimuli induce epigenetic
changes, which increase a genetically mediated risk of
disease [6]. If it is the case that differential methylation
proﬁles contribute to the risk of adverse health, there is
potential utility in using epigenetic data in the prediction of
health outcomes. In the current study, we test whether
methylation proﬁles associate with adverse health out-
comes. We examine (1) cross-sectional associations
between an epigenetic score for BMI and health-related,
cognitive, psychosocial and lifestyle outcomes, and (2)
whether an epigenetic BMI score accounts for variance in
these outcome variables independently of phenotypic BMI.
Research design and methods
The Lothian Birth Cohorts 1921 and 1936
The Lothian Birth Cohorts 1921 (LBC1921) and 1936
(LBC1936) are follow-up studies of the Scottish Mental
Surveys of 1932 and 1947, respectively [7, 8]. These sur-
veys tested the intelligence of 87,498 children (in 1932) and
70,805 children (in 1947) in Scotland at the age of 11 years,
using the Moray House Test number 12. Approximately 60
years later, individuals who had taken the original tests and
were living in Edinburgh and the Lothians were contacted,
of whom 550 were recruited to the LBC1921 and 1091 to
the LBC1936. Members of the LBC have since provided a
wealth of cognitive, neuropsychological, psychosocial,
biological (including genomic and other 'omics) and neu-
roimaging data longitudinally as part of the LBC
study, which is ongoing [7, 8]. Recruitment and testing
of the LBC1921 and LBC1936 have been described else-
where [9, 10].
Ethics
Ethical permissions for the LBC1921 were obtained from
the Lothian Research Ethics Committee (LREC/1998/4/
183). Permissions for the LBC1936 were obtained from the
Multi-Centre Research Ethics Committee for Scotland
(MREC/01/0/56) and the Lothian Research Ethics Com-
mittee (LREC/2003/2/29). Written informed consent was
obtained from all participants.
DNA methylation
DNA methylation data were assessed in whole blood sam-
ples from the LBC1921 and LBC1936 using the Illumina
HumanMethylation450 BeadChip (Illumina Inc., San
Diego, CA, USA). Full details of sample preparation and
methylation typing have been reported previously [11]. In
brief, background correction was performed and quality
control was used to remove probes with a low detection rate
(p > 0.01 for >5% of samples), low quality (manual
inspection), low call rate (p < 0.01 for <95% of probes), and
samples with a poor match between genotypes and single
nucleotide polymorphism (SNP) control probes, and with
incorrectly predicted sex.
The regression weights for the LBC1921 and LBC1936
BMI epigenetic signatures were derived from an indepen-
dent cohort—Generation Scotland: the Scottish Family
Health Study (GS; [12, 13]). Full details are provided in
Supplementary Appendix 1.
Phenotypic data
Continuous outcome measures formed six categories:
(1) Physical health
Physical health variables included height (cm),
weight (kg), BMI (kg/m2), time taken to walk 6 m (s),
grip strength (kg; measured using a North Coast
Hydraulic Hand Dynamometer, JAMAR: Lafayette,
Indiana, USA) and lung function (litres; forced
expiratory volume in 1 s measured using a Micro
Medical Spirometer). A measure of general physical
health was also calculated using the ﬁrst unrotated
component of a principal component analysis of 6m
walk time, grip strength and lung function.
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(2) Mental health
Recent mood state was measured using the
Hospital Anxiety and Depression Scale (HADS;
[14]). The scale includes seven items for anxiety
and seven items for depression and has a maximum
score of 21, with scores of 11 or over indicating
probable anxiety or depression.
(3) Cognitive ability
Variables measuring cognitive ability included the
following subtests of the Wechsler Adult Intelligence
Scale III (WAIS; [15]): Symbol Search and Digit
Symbol Coding to assess speed of information
processing, Matrix Reasoning to assess non-verbal
reasoning, Letter-Number Sequencing and Backward
Digit Span to assess working memory, and Block
Design to assess constructional ability. The National
Adult Reading Test (NART; [16]) was included as a
measure of prior (or crystallised) cognitive ability.
Finally, a measure of general ﬂuid intelligence was
calculated using the ﬁrst unrotated component of a
principal components analysis of the WAIS-III
subtests described above.
(4) Psychosocial factors
Personality traits were measured using the 50-item
version of the International Personality Item Pool
questionnaire (IPIP; [17]). This questionnaire consists
of ten items for measuring ﬁve personality factors:
Extraversion, Agreeableness, Conscientiousness,
Emotional Stability, and Intellect. We also included
the World Health Organisation Quality of Life
assessment (WHOQOL-BREF; [18]). This question-
naire produces scores for four domains related to
quality of life: physical health, psychological, social
relationships, and environment.
(5) Bloods and biomarkers
Blood samples were taken to assess glycated
haemoglobin (%total HbA1c), ﬁbrinogen (g/l), C-
reactive protein (mg/l), triglycerides (mmol/l), total
cholesterol (mmol/l) and high-density lipoprotein
cholesterol (HDL; mmol/l). A HDL ratio was
calculated by dividing HDL by total cholesterol.
Total cholesterol levels were adjusted for individuals
on lipid-lowering medications. Systolic and diastolic
blood pressure, both sitting and standing, was
measured at our research facility with an Omron
705IT monitor (Milton Keynes, UK). Blood pressure
scores were adjusted for individuals taking antihy-
pertensive medications.
(6) Lifestyle factors
Social deprivation was measured using the Scottish
Index of Multiple Deprivation (SIMD; [19]). The SIMD
ranks geographical areas in Scotland based on current
income, employment, health, education, skills and training,
geographic access to services, housing and crime. The
SIMD provides a standardised measure of relative depri-
vation throughout Scotland. In the present study, a lower
score indicates a greater level of deprivation. Units of
alcohol consumed per week and physical activity were
reported by participants during a structured interview with a
member of the LBC research team. Physical activity was
coded as follows: (1) “household chores” (2) “walking etc.
1–2 times a week”, (3) “walking etc. several times a week”,
(4) “exercise 1–2 times a week”, (5) “exercise several times
a week”, (6) “keep-ﬁt/heavy exercise/sport several times a
week”. Dietary data were derived from the Scottish Colla-
borative Group 168-item Food Frequency Questionnaire,
version 7.0 [20, 21], in which participants are asked to
indicate how much of certain foods they have consumed in
the past 2–3 months. The dietary patterns measured in the
current study are Mediterranean diet, health-aware diet,
traditional diet, and sweet foods. Dietary patterns were
extracted via principal components analysis with orthogonal
rotation from all FFQ items. Further details on the con-
struction of the dietary patterns and food types associated
with each pattern are available in Corley et al. [22].
Participants reported their disease history during a
structured interview with a member of the LBC research
team. Self-reported disease history variables were binary
and included: high blood pressure, type 1 diabetes mellitus,
type 2 diabetes mellitus, high cholesterol, cardiovascular
disease, leg pain, poor blood circulation, stroke, neoplasm,
health issues related to the thyroid, Parkinson’s disease,
arthritis and allergies.
Descriptive statistics for all continuous outcome vari-
ables from LBC1936 and LBC1921 are presented in
Table S1. Further information on data collection and
laboratory procedures can be found in published protocols
for the ﬁrst waves of data collection for the LBC1921 [9]
and LBC1936 [10].
Statistical analyses
Linear regression models were used to investigate the
relationship between the epigenetic BMI score and outcome
variables. For each model, the R2 statistic represents the
proportion of variance in the outcome variable that can be
accounted for by the epigenetic BMI score (see model 1),
phenotypic BMI score (model 2), and both epigenetic BMI
and phenotypic BMI scores together (model 3). To estimate
the proportion of variance accounted for by these predictors
without the effect of covariates, the R2 statistic represents
the difference between the R2 of the null model (see below)
and the R2 of models 1, 2 and 3, respectively. Age at the
time of testing and sex were included as covariates in all
models. Height was included as an additional covariate in
An epigenetic score for BMI based on DNA methylation correlates with poor physical health and major. . .
models for time taken to walk 6 m, forced expiratory
volume (lung function) and general physical health. The
models are as follows:
Model 1: variable of interest ~ epigenetic BMI score+
age at time of testing+ sex.
Model 2: variable of interest ~ phenotypic BMI+ age at
time of testing+ sex.
Model 3: variable of interest ~ epigenetic BMI score+
phenotypic BMI+ age at time of testing+ sex.
Null model: variable of interest ~ age at time of
testing+ sex.
Logistic regressions were conducted for self-reported
disease history variables as these had binary outcomes
(disease/no disease). Similar to the models above, logistic
regressions were carried out for each variable to test whe-
ther epigenetic BMI, phenotypic BMI, and an additive
model with both epigenetic BMI score and phenotypic BMI
as predictor variables, were associated with disease history.
For all analyses carried out using LBC1936 data, a Bon-
ferroni corrected level of signiﬁcance was used (p < 0.05/
n_tests= 0.00026). Analyses were carried out in R version
3.4.0 [23].
Sensitivity analysis
For variables that associated with epigenetic BMI, we car-
ried out sensitivity analyses, by including a polygenic score
for BMI (for details, see Supplementary Appendix 2) as a
predictor in the additive model together with epigenetic
BMI score and phenotypic BMI (model 4).
Model 4: variable of interest ~ epigenetic BMI score+
phenotypic BMI+ polygenic BMI score+ age at time of
testing+ sex.
Replication analyses in the LBC1921
Signiﬁcant associations between epigenetic BMI score and
outcome variables were tested for replication in an inde-
pendent sample, the LBC1921. Prior to testing, we carried
out power analyses based on the effect sizes of associations
in the LBC1936, to assess whether the sample size for each
variable in the LBC1921 was large enough to detect a
signiﬁcant effect (80% power, α= 0.05). For all
analyses carried out using LBC1921 data, a Bonferroni
corrected level of signiﬁcance was used (p < 0.05/n_tests=
0.0045).
Results
Analyses of the LBC1936 included 892 individuals (female,
n= 440, 49.3%), with a mean age of 69.5 years.
Epigenetic BMI score is associated with outcomes
related to poor physical health, biomarkers of
metabolic syndrome and social deprivation
Only associations with a p value < 0.00026 (i.e. after Bon-
ferroni correction) are presented here—full results are pre-
sented in Table S2.
The results of the linear regression models showed that
epigenetic BMI was strongly associated with phenotypic BMI
(p < 2 × 10–16) and accounted for 10% of its variation.
Increases in epigenetic BMI score also correlated with poorer
performance on other physical health variables: as epigenetic
BMI score increased by 1 SD, time taken to walk 6m
increased by 0.14 s (p= 2.5 × 10−05, R2= 0.02), body weight
increased by 0.24 kg (p= 4.1 × 10−16, R2= 0.06),
forced expiratory volume decreased by 0.13 l (p= 1.1 × 10–07,
R2= 0.02), and general physical health decreased by 0.13
SDs (p= 1 × 10−07, R2= 0.02).
Regarding blood and biomarker variables, epigenetic
BMI score was associated with higher levels of %total
HbA1c (p= 1.1 × 10−13, R2= 0.06), triglycerides (p < 2 ×
10−16, R2= 0.09), and HDL ratio (HDL cholesterol/total
cholesterol; p= 2.4 × 10−07, R2= 0.03), and lower levels of
HDL cholesterol (HDL; p < 2 × 10−16, R2= 0.08).
Finally, epigenetic BMI score was associated with lower
physical health-related quality of life (p= 4 × 10−5, R2=
0.02), lower scores on the Scottish Index of Multiple
Deprivation (p= 9.9 × 10−05, R2= 0.02), and lower levels
of self-reported physical activity (p= 1.6 × 10−04, R2=
0.02).
Epigenetic BMI score and phenotypic BMI account
for independent proportions of variance
Phenotypic BMI was associated with greater time taken to
walk 6 m (p= 2.6 × 10−16, R2= 0.07), greater body weight
(p < 2 × 10−16, R2= 0.62), poorer general physical health
(p= 7.1 × 10−11, R2= 0.02), higher levels of %total HbA1c
(p= 3.6 × 10−13, R2= 0.06), higher levels of triglycerides
(p= 2.2 × 10−15, R2= 0.07), higher HDL ratio (p= 3.3 ×
10−07, R2= 0.03), lower levels of HDL cholesterol (p < 2 ×
10−16, R2= 0.08), poorer physical health-related quality of
life (p= 1.3 × 10−14, R2= 0.07), and lower levels of self-
reported physical activity (p= 4.4 × 10−07, R2= 0.03). With
the exception of triglycerides, phenotypic BMI accounted
for a greater or equal amount of variance of all outcome
variables, relative to epigenetic BMI.
Linear regression models with both epigenetic and phe-
notypic BMI scores as predictor variables, demonstrated
that epigenetic and phenotypic BMI explain partially inde-
pendent proportions of variance in the outcome variable.
This pattern was most striking for biomarker variables
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related to metabolic syndrome— models that demonstrated
associations with these biomarkers are presented in Fig. 1.
Epigenetic BMI score is associated with self-reported
disease history
The epigenetic BMI score (per SD) was positively asso-
ciated with type 2 diabetes (OR 2.17, 95% CI 1.67, 2.84),
cardiovascular disease (OR 1.45, 95% CI 1.24, 1.71), and
high blood pressure (OR 1.30, 95% CI 1.13, 1.49). Pheno-
typic BMI was associated with type 2 diabetes (OR 1.83,
95% CI 1.45, 2.31) and high blood pressure (OR 1.55, 95%
CI 1.34, 1.80). In an additive model with both epigenetic and
phenotypic BMI scores as predictors, epigenetic BMI score
was associated with type 2 diabetes (OR 1.92, 95% CI 1.45,
2.55) and cardiovascular disease (OR 1.39, 95% CI 1.18,
1.65) - all associations signiﬁcant at p < 0.00026. Full results
of these logistic regression models are presented in Table S3.
Replication of associations with epigenetic BMI
score in LBC1921
Analyses of the LBC1921 included 433 individuals (female,
n= 263, 60.7%), with a mean age of 79.1 years. Where
possible, variables that associated with epigenetic BMI
score in the LBC1936 (n= 15) were tested for replication in
the LBC1921. Some variables were not available in the
LBC1921 (n= 5) and we did not have sufﬁcient statistical
power to detect the effects for several others (n= 2). Only
associations with a p value < 0.0045 (i.e. after Bonferroni
correction) are presented in Table 1—full results are pre-
sented in Tables S4 and S5. In the LBC1921, associations
were found between epigenetic BMI score and body weight,
BMI, physical health-related quality of life, %total HbA1c,
and triglyceride levels.
A polygenic score for BMI did not increase R2 of the
additive models in LBC1936
Tables S6 and S7 present the results of the linear and
logistic regression models in which a polygenic score for
BMI was included as a predictor variable alongside epige-
netic BMI score and phenotypic BMI. In these additive
models, a polygenic BMI score did not associate with any
of the variables tested. In a linear regression model with
both epigenetic BMI score and polygenic BMI score as
predictor variables, polygenic BMI demonstrated a strong
association with phenotypic BMI (p < 2 × 10−16) and toge-
ther, predictors accounted for 18% of the variation in phe-
notypic BMI.
Discussion
Using DNA methylation data, we constructed an epigenetic
score for BMI to test its association with health, cognitive
Table 1 Replication of
associations between epigenetic
BMI and outcome variables in
the LBC1921
Epigenetic BMI
n Standardised β SE Raw p= R2
Physical health
Weight (kg) 433 0.198 0.04 2.71 × 10−06 0.04
BMI (kg/m2) 432 0.246 0.05 3.31 × 10−07 0.06
Psychosocial
WHOQOL: physical health 378 −0.162 0.05 0.002 0.02
Bloods and biomarkers
HbA1c (%total) 379 0.270 0.05 9.72 × 10−08 0.07
Triglyceride (mmol/L) 421 0.262 0.05 3.22 × 10−08 0.07
Raw p values lower than the Bonferroni-corrected level of signiﬁcance (α= 0.0045) are presented in bold
Fig. 1 Plot of R2 statistics from linear regression analyses in which
epigenetic BMI, phenotypic BMI and epigenetic+ phenotypic BMI,
respectively, associated with biomarker variables at p < 0.00026. The
plots demonstrate the general pattern observed, with the additive
model accounting for a greater proportion of variance in the outcome
variable than models including epigenetic BMI score only, or phe-
notypic BMI only
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and lifestyle outcomes in the LBC1936. We found that
a higher epigenetic score for BMI is associated with poorer
physical health (body weight, time taken to walk 6 m, lung
function and general physical health), higher levels of
HbA1c and triglycerides, higher HDL ratio, lower HDL
cholesterol, lower physical health-related quality of life,
lower self-reported physical activity and greater social
deprivation. We replicated several of these associations
(BMI, weight, physical health-related quality of life, HbA1c
and triglycerides) in an independent, older sample, the
LBC1921. Our analysis of the LBC1936 also showed that
epigenetic BMI score is associated with self-reported type 2
diabetes, cardiovascular disease and high blood pressure:
health outcomes for which obesity is a major risk factor. An
association between an epigenetic score for BMI and type 2
diabetes, identiﬁed via clinical diagnosis or HbA1c ≥6.5%,
has previously been reposted by Wahl et al. [2].
In almost all analyses, phenotypic BMI accounted for a
greater proportion of variance in outcome variables than
epigenetic BMI, but phenotypic and epigenetic BMI scores
together accounted for a greater proportion of variance still.
This additive effect suggests that epigenetic and phenotypic
BMI scores account for at least partially independent pro-
portions of variance. It is possible that some of these par-
tially independent associations are driven by correlations
between the CpG probes used to create the epigenetic BMI
score, and the outcome variables of interest. This could
mean that our epigenetic score for BMI is capturing the
downstream effects of obesity, such as biological processes
associated with poor metabolic health, which phenotypic
BMI (a more ‘blunt’ measure of metabolic health) does not
account for directly.
We found that an epigenetic score for BMI accounted for
10% of the variance in phenotypic BMI, a higher proportion
than that reported by Shah et al. [5], whose epigenetic BMI
score accounted for 6.9% of the variance in phenotypic
BMI in the LBC1936. This improvement could be due to
our larger discovery sample (2562 vs. 1366), and/or because
weights for our epigenetic BMI score were calculated using
a single regression model, with BMI residuals as the out-
come and CpGs as predictors, rather than separate models
for each CpG predictor (see Supplementary Appendix 1).
Shah et al. also found that an epigenetic BMI score
increased the phenotype prediction when combined with a
genetic score for BMI from 8% to 14% [5]. By including
both an epigenetic and a polygenic score for BMI as pre-
dictors in our linear regression model, we improved the
proportion of variance in phenotypic BMI explained from
10% to 18%. However, our polygenic score for BMI did not
associate with any outcome variables when included
alongside epigenetic and phenotypic BMI scores as pre-
dictors in regression models. In the majority of these
models, polygenic BMI score had little effect; associations
between epigenetic BMI score and outcome variables
remained, particularly for physical health and biomarker
variables. It could be the case that the epigenetic BMI score
encompasses the interaction between the polygenic BMI
score and outcome variables implicated in biological pro-
cesses related to obesity (as opposed to cognitive or lifestyle
variables). If this is the case, there appears to be little beneﬁt
in the inclusion of a polygenic score for BMI alongside
epigenetic BMI and phenotypic BMI scores, when testing
associations with biological and physical health-related
variables.
Our results demonstrate that BMI (and epigenetic BMI)
is associated with obesity-related adverse health and thus, is
a clinically relevant metric for measuring body mass.
However, the BMI has been criticised due to its assumption
that a low body mass equates to metabolic health. Dvorak
et al. [24] found that BMI failed to distinguish between
healthy individuals and individuals who were metabolically
unhealthy, but of normal weight despite differences in total
fat mass, body fat percentage, subcutaneous fat and visceral
abdominal adiposity. It has also been shown that waist to
height ratio (WHtR) and waist/height0.5 (WHT.5R) are
better predictors of whole body fat percentage and visceral
adipose tissue mass than BMI [25]. Despite this, the BMI
continues to be widely used in clinical settings. A devel-
opment upon this study would be to test whether an epi-
genetic score based on WHtR or WHT.5R can further
increase the proportion of variance in obesity-related out-
comes explained by epigenetic BMI.
That our replication sample (the LBC1921) was smaller
than our discovery sample (the LBC1936) is a limitation of
this study. While we were able to replicate ﬁve out of eight
associations with epigenetic BMI score in the LBC1936, the
smaller sample size of the LBC1921 prevented us from
testing a greater number of associations due to a lack of
power. A further limitation of this study is the inability to
make strong directional inferences; it is impossible to tell
whether differential DNA methylation is a mediator of the
causal disease pathway, or occurs in response to disease
processes. Recent progress has been made in this area using
a Mendelian Randomisation approach [26], which takes
SNPs as instruments for exposure variables, such as DNA
methylation, in order to gain insight into the direction of
causality. Longitudinal studies are another important
method for gaining insight into the role of DNA methyla-
tion in the pathophysiology of obesity-related disease.
Several studies have analysed DNA methylation from
umbilical cord blood as a baseline measure for longitudinal
epigenetic data. This is then analysed in tandem with
longitudinal data on health-related outcomes in order to
capture epigenetic changes that may predate disease onset
[27]. These cohorts must have deep phenotyping of lifestyle
and environmental factors (including prenatal factors such
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as maternal diet and smoking), which may confound epi-
genetic changes. Another developing line of research is
investigating epigenetic changes associated with weight-
loss interventions such as diet programmes or gastric bypass
surgery [28, 29].
A recent study by Richmond et al. [30] combined several
of these methods to investigate causality between BMI and
methylation at HIF3A (a gene linked to metabolism and
obesity, and associated with adiposity in multiple EWAS
[31, 32]), including bidirectional Mendelian randomisation
analysis, longitudinal analysis of HIF3A methylation, and
analysis of association between maternal pregnancy BMI
and HIF3A methylation in offspring at birth (using cord
blood). The results across each method indicated that a
higher BMI causally inﬂuenced higher HIF3A methylation,
suggesting that alterations in DNA methylation are a
downstream effect of obesity. Further longitudinal studies
and studies of naturalistic interventions are needed to elu-
cidate the direction of causal association between obesity
and DNA methylation, and to provide mechanistic insight
into the pathophysiology of obesity-related disease.
We have demonstrated that an epigenetic score for BMI
is associated with poorer physical health, poorer health-
related quality of life, biomarkers for metabolic syndrome,
physical inactivity, social deprivation and major diseases for
which obesity is a risk factor. We replicated the associations
between BMI, body weight, HbA1c, triglycerides and
physical health-related quality of life in an independent,
older cohort. An epigenetic score for BMI based on DNA
methylation increased the amount of variance in health
outcomes accounted for by phenotypic BMI score alone,
demonstrating the value in using epigenetic information for
constructing more accurate risk prediction for obesity-
related biomarkers, health conditions and disease.
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